U.S., April 17 -- ClinicalTrials.gov registry received information related to the study (NCT07532876) titled 'Comparison of Elagolix and OCPs in Reducing Endometriosis Associated Pelvic Pain' on Sept. 17, 2025.
Brief Summary: This study is designed to provide direct evidence on the relative effectiveness and safety of Elagolix versus OCPs, helping physicians make more tailored treatment decisions.
Study Start Date: May 01
Study Type: INTERVENTIONAL
Condition:
Endometriosis (Diagnosis)
Intervention:
DRUG: Elagolix
Elagolix will be administered at 150 mg once daily in this study.
DRUG: Oral Contraceptive (OC)
In this study, administered once daily in a continuous 28-day cycles for 3 months
Recruitment Status: ENROLLING_BY_INVITATIO...